No Data
Cybin Inc. Shareholders Approve Key Decisions
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
Cybin Inc. Advances Neuropsychiatric Drug Development
Press Release: Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
No Data